Both diseases are characterized by oxidative stress and lipid metabolism disorders
Thus, to maximize therapeutic outcomes, novel designs are required to advance the facile integration of different therapeutics onto platelet carriers, progressively improve both binding and penetration in atherosclerotic lesions, and ensure on-demand drug delivery to plaque macrophages
Review of ginsenosides targeting mitochondrial function to treat multiple disorders: Current status and perspectives
Complementary DNA (cDNA) was made by reverse transcription of RNA (2 g) using Moloney murine leukemia virus reverse transcriptase (Promega, Madison, MI, USA) and labeled with Biotin-16-2-deoxy-uridine-5-triphosphate (Roche Diagnostics, Indianapolis, IN, USA)
These involve normal epithelial and fibroblast cells via upregulation of telomerase